Drug intelligence / Profile preview

EM2D9

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

EM2D9 is a **monoclonal antibody** developed to target **integrin α5β1**, a cell surface adhesion receptor. In preclinical models of endometrial cancer, EM2D9 specifically recognizes endometrial cancer cells, inhibits their migration, and downregulates CD151 mRNA expression, likely affecting the FAK (Focal Adhesion Kinase) signaling pathway. These actions suggest EM2D9 may disrupt tumor cell motility and invasiveness, indicating potential as a novel immunotherapy or targeted therapy for endometrial carcinoma[1][5].

Targets

ITGA5:ITGB1 (Integrin α5β1)

Beyond the preview

Go deeper on EM2D9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EM2D9.

Explore the full profile